Shares rose modestly by 2.2% following the quarter, reflecting investor acknowledgment of meaningful progress in pancreatic cancer programs and regulatory milestones, although the reaction suggests some caution remains on near-term commercial ramp or broader pipeline clarity.
- Positive clinical data from the Phase III RASolute 302 trial demonstrated improvements in overall survival, progression-free survival, and quality of life for daraxonrasib in metastatic pancreatic cancer.
- The FDA has accepted the new drug application for daraxonrasib, and the EMA has prioritized the drug for accelerated review under its Cancer Medicines Pathfinder initiative.
- Expanded access program approved over 90% of requests, delivering daraxonrasib to more than 2,000 patients across nearly all U.S. states and Puerto Rico.
- Commercial infrastructure for daraxonrasib’s U.S. launch is fully in place, including sales, medical affairs, and patient services.
- Multiple Phase III studies continue enrolling for daraxonrasib and zoldonrasib in first-line and adjuvant pancreatic cancer settings, along with a novel combination trial, supporting a broad development strategy.
Community Discussion